In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
News|Podcasts|April 13, 2026
ACT Brief: Clinical Trial Trends and 2026 Outlook, AI Agents and Workforce Transformation, and Degrader-Antibody Conjugate Partnership
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we explore industry perspectives on operational and methodological shifts defining 2026, how agentic AI will augment clinical trial roles over the next two years, and Roche's expanded partnership with C4 Therapeutics on next-generation antibody conjugates.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In a new ACT
video , industry leaders discussed 2026 trends including site operational burden, patient access expansion beyond established centers, AI implementation moving from pilots into daily operations, and methodological shifts toward analyzing multiple outcomes in single primary analyses. The consensus pointed to balancing efficiency with equity in trial design. - In a new
Q&A , building on his recent videointerview , Krishna Cheriath, VP and head of clinical research digital data and AI at Thermo Fisher Scientific, introduced an augmentation scale defining how agentic AI will reshape trial roles from level zero through level four over the next two years. Successful adoption requires reimagining business processes for AI-by-design, upskilling talent to use it wisely, and workforce planning now to manage the transition from human to human-plus-digital roles. - Roche and C4 Therapeutics expanded their
partnership with a $1 billion collaboration to develop degrader-antibody conjugates combining targeted protein degradation with antibody-drug conjugation. The approach introduces a catalytic mechanism of action intended to improve therapeutic index versus conventional cytotoxic ADC payloads, with two initial programs targeting undisclosed oncology indications.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
Trending on Applied Clinical Trials Online
1
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
2
FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine
3
Beyond the Molecule: Why Radiopharmaceutical Trials Require a New Operating Model
4
Operation TrialBlazer Leveraging New and Anticipated US Policy Changes in Early Development
5